Recent data reveals that up to 30% of FDA submissions now focus on combination products. In our latest article, we explore their definition and their diverse categories, including the fusion of drugs, devices, and biological products.
The allure of combination products is based in their myriad benefits: From localized treatment and streamlined processes to minimized contamination risks and precise dosage control, they are elevating patient treatment and care.